Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Drops By 19.0%

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 1,790,000 shares, a decrease of 19.0% from the October 15th total of 2,210,000 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average daily volume of 458,300 shares, the days-to-cover ratio is currently 3.9 days.

Compass Therapeutics Trading Down 13.2 %

Shares of NASDAQ:CMPX traded down $0.21 on Friday, hitting $1.38. 1,348,934 shares of the company were exchanged, compared to its average volume of 455,768. The stock’s 50 day moving average price is $1.75 and its 200 day moving average price is $1.42. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The firm has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, equities analysts predict that Compass Therapeutics will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC increased its holdings in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares in the last quarter. Rovin Capital UT ADV acquired a new position in Compass Therapeutics in the 3rd quarter worth about $25,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics in the third quarter valued at approximately $30,000. Finally, Geode Capital Management LLC increased its position in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after buying an additional 19,095 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CMPX has been the topic of several analyst reports. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $5.00 to $4.00 in a research note on Friday. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $6.75.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.